Dr. Hamid Emamekhoo, MD
Claim this profileUniversity of Wisconsin Carbone Cancer Center
Studies Prostate Cancer
Studies Cancer
11 reported clinical trials
21 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
DDRD negative
MMR-d positive
2Cancer
Stage IV
BRAF positive
MSI-H positive
Affiliated Hospitals
Clinical Trials Hamid Emamekhoo, MD is currently running
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting1 award Phase 221 criteria
RP1 + Nivolumab
for Cancer
This trial tests a modified virus (RP1) and an immune-boosting drug (nivolumab) in adults with advanced or treatment-resistant solid tumors. RP1 kills cancer cells and helps the immune system recognize them, while nivolumab enhances the immune response. Nivolumab has been approved for treating advanced melanoma, renal cell carcinoma, non-small cell lung cancer, and other malignancies.
Recruiting1 award Phase 29 criteria
More about Hamid Emamekhoo, MD
Clinical Trial Related2 years of experience running clinical trials · Led 11 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Hamid Emamekhoo, MD has experience with
- Nivolumab
- Ipilimumab
- Cabozantinib
- PTVG-HP
- Docetaxel
- Androgen Deprivation Therapy
Breakdown of trials Hamid Emamekhoo, MD has run
Prostate Cancer
Cancer
Uterine Tumors
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Hamid Emamekhoo, MD specialize in?
Hamid Emamekhoo, MD focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are DDRD negative.
Is Hamid Emamekhoo, MD currently recruiting for clinical trials?
Yes, Hamid Emamekhoo, MD is currently recruiting for 2 clinical trials in Madison Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Hamid Emamekhoo, MD has studied deeply?
Yes, Hamid Emamekhoo, MD has studied treatments such as Nivolumab, Ipilimumab, Cabozantinib.
What is the best way to schedule an appointment with Hamid Emamekhoo, MD?
Apply for one of the trials that Hamid Emamekhoo, MD is conducting.
What is the office address of Hamid Emamekhoo, MD?
The office of Hamid Emamekhoo, MD is located at: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin 53705 United States. This is the address for their practice at the University of Wisconsin Carbone Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.